White Papers

impact medicom, medical communications, agency

Canadian perspective on managing MM during the COVID-19 pandemic: Lessons learned and future considerations (2020)


medical communications, media, impact, medical writing, agency

Management of CLL in Canada during the coronavirus pandemic (2020)

medical communications, media, impact, medical writing

Review of BTK inhibitors for the treatment of relapsed or refractory MCL (2019)

medical communications, media, medical writing, impact

Multidisciplinary perspective on the SC administration of trastuzumab in HER2-positive breast cancer (2019)

medical communications, media, medical writing, agency, impact

Update on the SC administration of rituximab in Canadian cancer centres (2020)

impact medicom, impact, medical communications, medical writing

Emerging therapies for the treatment of relapsed or refractory DLBCL (2019)

medical communications, medical writing, media, impact

Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective (2018)

impact, impact medicom, medical communications, media

Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss (2017)

Use of minimal residual disease assessment in the treatment of CLL (2017)

A Canadian perspective on the SC administration of rituximab in NHL (2017)

impact medicom, medical communications, media, medical writing

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and MCL (2016)

impact medicom, medical communications, media

Emerging therapies for the treatment of relapsed or refractory FL (2016)

impact medicom, medical communications, media, medical writing

Novel regimens prior to ASCT for the management of adults with relapsed/refractory NHL and HL (2016)

impact medicom, medical communications, medical writing, media

A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in CLL (2016)

impact medicom, medical communications, medical writing, media

Expanded-access trial of bendamustine in patients with rituximab-refractory indolent NHL or untreated CLL: BEND-ACT (2015)

Tel. 416-434-8923

Email. info@impactmedicom.com